Navigation Links
VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
Date:12/29/2009

erage baseline weight of 256 pounds; in CONQUER, the average baseline BMI of the study population was 36.6 kg/m(2) with an average baseline weight of 227 pounds. All patients were asked to follow a hypocaloric diet representing a 500-calorie/day deficit and advised to implement a simple lifestyle modification program.

About Qnexa

Qnexa (Q-NEX-uh) is an investigational drug being developed to address weight loss. Qnexa is a once-a-day, proprietary, oral, controlled-release formulation of low dose phentermine and topiramate, which is believed to address both appetite and satiety - the two main mechanisms that impact eating behavior - in one capsule. In phase 2 and 3 clinical studies, Qnexa has demonstrated significant weight loss, glycemic control, and improvement in cardiovascular risk factors.

About VIVUS

VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead product in clinical development, Qnexa, has recently completed phase 3 clinical trials for the treatment of obesity and an NDA was submitted to the FDA in December 2009. Qnexa is currently in phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a potentially best-in-class PDE5 inhibitor, and in phase 2 development of Luramist(TM) for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE® (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.

Certain stateme
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Results From Phase 3 EQUATE Trial of VIVUS Qnexa Highlighted at European Congress on Obesity
2. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
3. Data on VIVUS Qnexa to be Featured at European Association for the Study of Diabetes Annual Meeting
4. VIVUS Announces Promotion of Peter Tam to President
5. VIVUS to Present at Lazard Capital Markets Healthcare Conference
6. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
7. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
8. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
9. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
10. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)...  Zebra Imaging, Inc., the world,s foremost provider ... strategic partnership with the Zygote Media Group Inc., ... biomedical models for animation and visual effects, to ... maintains the world,s most comprehensive library of accurate ... development of high-end solid 3D anatomy models for ...
(Date:10/31/2014)... October 31, 2014 Oramed ... pharmaceutical company focused on the development of oral ... host a conference call to discuss the clinical ... ORMD-0801, the company,s proprietary oral insulin capsules, to ... 2014 at 10:00 a.m. Eastern time. ...
(Date:10/31/2014)... 2014  Zacks.com announces the list of stocks featured in the ... latest news and events impacting stocks and the financial markets. Stocks ... - Free Report ), Celgene (Nasdaq: CELG ... - Free Report ), Market Vectors Biotech ETF (AMEX: ... (AMEX: XBI - Free Report ). ...
Breaking Medicine Technology:Zebra Imaging and Zygote Media Partner to Bring 3D Visualization to the Medical Community 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 2The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 3The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 4The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 5The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 6The Zacks Analyst Blog Highlights: Amgen, Celgene, Biogen Idec, Market Vectors Biotech ETF and SPDR S&P Biotech ETF 7
... Knopp Neurosciences Inc. ("Knopp"),today announced the ... of KNS-760704, a,small molecule therapy in development ... (Logo: http://www.newscom.com/cgi-bin/prnh/20070924/KNOPPLOGO ) ... in healthy volunteers is being closely followed ...
... planning,use prevents over one million HIV-positive births worldwide ... the number of infants born with HIV,according to ... for Women With HIV," published by the INFO ... Center for Communication Programs. Women account for ...
Cached Medicine Technology:Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program 2Knopp Neurosciences Initiates Phase 1 Clinical Trial of KNS-760704 in ALS Development Program 3Hopkins Report: Focusing on Family Planning Lessens HIV Impact 2Hopkins Report: Focusing on Family Planning Lessens HIV Impact 3
(Date:10/31/2014)... Oct. 31, 2014 (HealthDay News) -- Access to generic ... patients will stick with their drug treatment, a new ... women with hormone receptor-positive breast cancer can reduce recurrence ... Hershman, an associate professor of epidemiology at Columbia University ... hospital news release. "However, work by our ...
(Date:10/31/2014)... Alan Mozes HealthDay ... In the world of 21st-century medicine, organ transplantation is nothing ... followed by the first liver transplant in 1963 and the ... even managed the transplantation of a patient,s entire face. ... entire human eye. But if one team of U.S. scientists ...
(Date:10/31/2014)... Each year, people across the United States spend an ... friends, which costs $522 billion, according to new research. ... on the time and wages that caregivers give up ... in daily activities. The study authors said the significant ... workplace flexibility policies. "Our findings provide a new ...
(Date:10/30/2014)... at Albert Einstein College of Medicine ... will present their latest aging research at ... Scientific Meeting. Topics include the identification of a ... cognitive impairment and the cellular biology of aging. ... in Washington, D.C., "Einstein-Montefiore has distinguished itself in ...
(Date:10/30/2014)... Tanaka and her research group at the DFG Research ... at the TU Dresden (CRTD) demonstrated for the first ... spinal cord in three dimensions from mouse embryonic stem ... dorsal interneurons along the dorsal/ventral axis was observed., This ... " Stem Cell Reports " on 30.10.2014 ., ...
Breaking Medicine News(10 mins):Health News:Generic Drugs May Help Breast Cancer Patients Stick to Therapy 2Health News:Scientists Set Their Sights on First Whole-Eye Transplant 2Health News:Scientists Set Their Sights on First Whole-Eye Transplant 3Health News:'Informal Care' for Older Americans Tops $500B Annually, Study Finds 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 3Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 4Health News:Reconstruction of a patterned piece of spinal cord in 3-D culture 2
... 30 Keck Graduate Institute (KGI) ... begin in January 2010, for those with an undergraduate degree ... skills before applying to medical school. , "We,re excited to ... medical professional," says Sheldon M. Schuster, PhD, KGI,s president. "Whether ...
... BEIJING, Sept. 30 /PRNewswire-Asia/ -- Sinovac Biotech ... products in China, announced today that,Sinovac has received its ... Ministry of Industry and Information Technology of the People,s,Republic ... purchase order,Sinovac is required to produce an additional 3 ...
... America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord ... ) focused on bringing the life saving potential ... nationwide and internationally, said today that it is opening ... laboratory in Las Vegas, as planned, the first ...
... National Breast Cancer Awareness Month and Topcor is introducing a ... October 5th, "Clipa for a Cure" is a special edition ... donate 10% of the retail price of every pink Clipa ... Society, breast cancer is the second leading cause of cancer ...
... Americans lack confidence that healthcare reform will deliver ... a survey released today by Thomson Reuters. , Forty-one ... make healthcare more affordable. When sorted by political ... divisions along party lines: 72 percent of Democrats said ...
... , LUDWIGSHAFEN, Germany, September 30 ... to cope with all the sustenance,we shove into it every ... the hardest substance that the human body produces. It consists ... questions of our Podcast listeners on Chemistry in our,everyday life. ...
Cached Medicine News:Health News:KGI Establishes Post Baccalaureate Premedical Program 2Health News:Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 2Health News:Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government 3Health News:Cord Blood America Opens Las Vegas Cryogenic Laboratory; Consolidates Offices in Nevada 2Health News:Cord Blood America Opens Las Vegas Cryogenic Laboratory; Consolidates Offices in Nevada 3Health News:'Clipa for a Cure': New Pink Instant Handbag Hanger Benefits Breast Cancer Research 2Health News:Thomson Reuters Survey: Americans Skeptical That Healthcare Reform Will Improve Quality or Affordability 2Health News:BASF Podcast: The Chemical Reporter - Why Does Fluoride Make Your Teeth Hard? 2Health News:BASF Podcast: The Chemical Reporter - Why Does Fluoride Make Your Teeth Hard? 3
This cannula's patented tip allows the simultaneous infusion of cardioplegia and aspiration of air from the aorta...
This cannula features a PVC body, auto inflatable smooth cuff, pressure monitoring line with integral stopcock....
...
... Select CAP® cannulae provides a simple ... readings. An innovative combination of aortic ... line, the Select CAP® can provide ... arterial pressure readings on which you ...
Medicine Products: